71.23

1.06% -0.76

After Hours: 71.23

Ani Pharmaceuticals Inc (ANIP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Ani Pharmaceuticals Inc stock is traded at $71.23, with a volume of 219.22K. It is down -1.06% in the last 24 hours and down -10.06% over the past month. ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Previous Close:

$71.99

Open:

$71.35

24h Volume:

219.22K

Relative Volume:

0.65

Market Cap:

$1.64B

Revenue:

$923.71M

Net Income/Loss:

$84.68M

P/E Ratio:

18.07

EPS:

3.9419

Net Cash Flow:

$182.81M

1W Performance:

-2.20%

1M Performance:

-10.06%

6M Performance:

-6.93%

1Y Performance:

-25.80%

1-Day Range:

$71.11

$72.06

1-Week Range:

$71.11

$74.99

52-Week Range:

$70.15

$99.50

Ani Pharmaceuticals Inc Stock (ANIP) Company Profile

Name

Ani Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

(609) 759-1810

Address

104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN

Employee

970

Twitter

Next Earnings Date

2026-08-07

Latest SEC Filings

ANIP's Discussions on Twitter

Compare ANIP vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIP Ani Pharmaceuticals Inc	71.23	1.78B	923.71M	84.68M	182.81M	3.9419
TAK Takeda Pharmaceutical Co Adr	18.45	57.90B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.36	42.89B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.60	43.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	75.81	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	487.61	22.35B	3.17B	1.29B	1.01B	27.09

Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-25	Initiated	H.C. Wainwright	Buy
Mar-14-25	Initiated	Jefferies	Buy
Mar-12-25	Initiated	JP Morgan	Overweight
Dec-11-24	Initiated	Leerink Partners	Outperform
Oct-11-24	Initiated	Piper Sandler	Overweight
Mar-15-24	Initiated	CapitalOne	Overweight
Aug-22-23	Reiterated	H.C. Wainwright	Buy
Mar-01-23	Initiated	Guggenheim	Buy
Sep-07-22	Initiated	H.C. Wainwright	Buy
Nov-02-21	Initiated	Truist	Buy
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform
Oct-16-17	Reiterated	Canaccord Genuity	Buy
Jul-31-17	Initiated	Canaccord Genuity	Buy
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy
Aug-05-15	Reiterated	Oppenheimer	Outperform
Aug-04-15	Reiterated	ROTH Capital	Neutral
Jul-31-15	Reiterated	Oppenheimer	Outperform
Jul-15-15	Reiterated	ROTH Capital	Neutral
Jun-23-15	Reiterated	Oppenheimer	Outperform
May-18-15	Reiterated	ROTH Capital	Neutral
May-06-15	Reiterated	Oppenheimer	Outperform
Apr-10-15	Downgrade	ROTH Capital	Buy → Neutral
Feb-26-15	Reiterated	ROTH Capital	Buy
Feb-18-15	Reiterated	Oppenheimer	Outperform

View All

Ani Pharmaceuticals Inc Stock (ANIP) Latest News

Aug 21, 2026

NFJ Investment Group LLC Takes $2.77 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Aug 21, 2026

Virtus Advisers LLC Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Aug 21, 2026

Aug 20, 2026

Quartz Partners LLC Makes New $1.61 Million Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Aug 20, 2026

Great Lakes Advisors LLC Buys Shares of 61,481 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Aug 20, 2026

Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Aug 20, 2026

Aug 19, 2026

ANI (ANIP): Rises 1.37% to $77.92 for the Current Session; Boundary Watch: $74.02 and $81.82 Define the Nearby Reference Levels for the Current SessionHigh Dividend Factor - Vinanet

Aug 19, 2026

ANI Pharmaceuticals (NASDAQ:ANIP): What Could Shift Sentiment? - Kalkine Media

Aug 19, 2026

Rice Hall James & Associates LLC Takes Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Aug 19, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 19, 2026

Aug 18, 2026

ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript - AOL.com

Aug 18, 2026

Aug 16, 2026

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance

Aug 16, 2026

Aug 15, 2026

ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold - Sahm

Aug 15, 2026

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance

Aug 15, 2026

Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Aug 15, 2026

Aug 14, 2026

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView

Aug 14, 2026

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth - Yahoo Finance

Aug 14, 2026

Aug 13, 2026

ANI Pharmaceuticals (ANIP) Insider Sell: SR. VP, GENERAL COUNSEL & SEC. Meredith Cook Sells 500 Shares - GuruFocus

Aug 13, 2026

ANI Pharmaceuticals Senior VP Meredith Cook Sells 500 Shares via 10b5-1 Trading Plan - Kalkine Media

Aug 13, 2026

Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat

Aug 13, 2026

ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan - Stock Titan

Aug 13, 2026

Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat

Aug 13, 2026

Aug 11, 2026

Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. By Investing.com - Investing.com Australia

Aug 11, 2026

Ori Gutwerg Sells 3,162 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat

Aug 11, 2026

Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. - Investing.com

Aug 11, 2026

ANI Pharmaceuticals (ANIP) SVP, Generics Ori Gutwerg Sells 3,162 Shares - GuruFocus

Aug 11, 2026

ANI Pharma SVP, Generics Ori Gutwerg reports sale of 3,162 common shares worth $243,474 - Bitget

Aug 11, 2026

ANI Pharmaceuticals (ANIP) SVP Ori Gutwerg sells 3,162 shares at $77 - Stock Titan

Aug 11, 2026

ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration - Yahoo Finance

Aug 11, 2026

Aug 10, 2026

Analysts cut ANI Pharmaceuticals targets despite Q2 earnings beat - scanx.trade

Aug 10, 2026

Guggenheim cuts ANI Pharmaceuticals stock price target on Cortrophin guidance - Investing.com

Aug 10, 2026

Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00 - MarketBeat

Aug 10, 2026

Canaccord cuts ANI Pharmaceuticals stock price target on Cortrophin miss By Investing.com - Investing.com Canada

Aug 10, 2026

Aug 09, 2026

ANI Pharmaceuticals (NASDAQ:ANIP): What Could Today Reveal? - Kalkine Media

Aug 09, 2026